• 1
    Brody H. Medicine's ethical responsibility for health care reform: the Top Five list. N Engl J Med 2010; 362: 2835.
  • 2
    Cassel CK, Guest JA. Choosing wisely: helping physicians and patients make smart decisions about their care. JAMA 2012; 307: 18012.
  • 3
    ABIM Foundation, American Board of Internal Medicine, ACP-ASIM Foundation, American College of Physicians-American Society of Internal Medicine, European Federation of Internal Medicine. Medical professionalism in the new millennium: a physician charter. Ann Intern Med 2002; 136: 2436.
  • 4
    Linstone A, Turoff M. The Delphi method: techniques and applications. Reading (MA): Addison-Wesley; 1975.
  • 5
    Charmaz K. Constructing grounded theory: a practical guide through qualitative analysis. Thousand Oaks (CA): Sage Publications; 2006.
  • 6
    Guyatt G, Gutterman D, Baumann MH, Addrizzo-Harris D, Hylek EM, Phillips B, et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians task force. Chest 2006; 129: 17481.
  • 7
    Hoffman A, Pearson SD. ‘Marginal medicine’: targeting comparative effectiveness research to reduce waste. Health Aff (Millwood) 2009; 28: w7108.
  • 8
    Kavanaugh A, Tomar R, Reveille J, Solomon DH, Homburger HA, and the American College of Pathologists. Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens. Arch Pathol Lab Med 2000; 124: 7181.
  • 9
    Solomon DH, Kavanaugh AJ, Schur PH, and the American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines. Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum 2002; 47: 43444.
  • 10
    Tozzoli R, Bizzaro N, Tonutti E, Villalta D, Bassetti D, Manoni F, et al. Guidelines for the laboratory use of autoantibody tests in the diagnosis and monitoring of autoimmune rheumatic diseases. Am J Clin Pathol 2002; 117: 31624.
  • 11
    Qaseem A, Alguire P, Dallas P, Feinberg LE, Fitzgerald FT, Horwitch C, et al. Appropriate use of screening and diagnostic tests to foster high-value, cost-conscious care. Ann Intern Med 2012; 156: 1479.
  • 12
    Thomson KF, Murphy A, Goodfield MJ, Misbah SA. Is it useful to test for antibodies to extractable nuclear antigens in the presence of a negative antinuclear antibody on Hep-2 cells? [letter]. J Clin Pathol 2001; 54: 413.
  • 13
    Cross LS, Aslam A, Misbah SA. Antinuclear antibodynegative lupus as a distinct diagnostic entity: does it no longer exist? QJM 2004; 97: 3038.
  • 14
    Slater CA, Davis RB, Shmerling RH. Antinuclear antibody testing: a study of clinical utility. Arch Intern Med 1996; 156: 14215.
  • 15
    Bahrt KM, McCarty GA. A negative fluorescent antinuclear antibody test in a patient with Jo-1 antibody. J Rheumatol 1985; 12: 6245.
  • 16
    Hoffman IE, Peene I, Veys EM, De Keyser F. Detection of specific antinuclear reactivities in patients with negative anti-nuclear antibody immunofluorescence screening tests. Clin Chem 2002; 48: 21716.
  • 17
    Dahle C, Skogh T, Aberg AK, Jalal A, Olcen P. Methods of choice for diagnostic antinuclear antibody (ANA) screening: benefit of adding antigen-specific assays to immunofluorescence microscopy. J Autoimmun 2004; 22: 2418.
  • 18
    Bossuyt X, Luyckx A. Antibodies to extractable nuclear antigens in antinuclear antibody-negative samples [letter]. Clin Chem 2005; 51: 24267.
  • 19
    American College of Rheumatology. Position Statement, methodology of testing for antinuclear antibodies. 2011. URL:
  • 20
    Centers for Disease Control and Prevention. Lyme disease diagnosis and treatment. 2011. URL:
  • 21
    American College of Physicians. Guidelines for laboratory evaluation in the diagnosis of Lyme disease. Ann Intern Med 1997; 127: 11068.
  • 22
    Hu LT. Lyme disease. Ann Intern Med 2012; 157: ITC21.
  • 23
    Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klempner MS, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006; 43: 1089134.
  • 24
    Fix AD, Strickland GT, Grant J. Tick bites and Lyme disease in an endemic setting: problematic use of serologic testing and prophylactic antibiotic therapy. JAMA 1998; 279: 20610.
  • 25
    Magri JM, Johnson MT, Herring TA, Greenblatt JF. Lyme disease knowledge, beliefs, and practices of New Hampshire primary care physicians. J Am Board Fam Pract 2002; 15: 27784.
  • 26
    Qureshi MZ, New D, Zulqarni NJ, Nachman S. Overdiagnosis and overtreatment of Lyme disease in children. Pediatr Infect Dis J 2002; 21: 124.
  • 27
    Ramsey AH, Belongia EA, Chyou PH, Davis JP. Appropriateness of Lyme disease serologic testing. Ann Fam Med 2004; 2: 3414.
  • 28
    Ley C, Le C, Olshen EM, Reingold AL. The use of serologic tests for Lyme disease in a prepaid health plan in California. JAMA 1994; 271: 4603.
  • 29
    Reid MC, Schoen RT, Evans J, Rosenberg JC, Horwitz RI. The consequences of overdiagnosis and overtreatment of Lyme disease: an observational study. Ann Intern Med 1998; 128: 35462.
  • 30
    Steere AC. Diagnosis and treatment of Lyme arthritis. Med Clin North Am 1997; 81: 17994.
  • 31
    Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64: 62539.
  • 32
    Combe B, Landewe R, Lukas C, Bolosiu HD, Breedveld F, Dougados M, et al. EULAR recommendations for the management of early arthritis: report of a Task Force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007; 66: 3445.
  • 33
    American College of Rheumatology Extremity Magnetic Resonance Imaging Task Force. Extremity magnetic resonance imaging in rheumatoid arthritis: report of the American College of Rheumatology Extremity Magnetic Resonance Imaging Task Force. Arthritis Rheum 2006; 54: 103447.
  • 34
    Machado PM, Koevoets R, Bombardier C, van der Heijde DM. The value of magnetic resonance imaging and ultrasound in undifferentiated arthritis: a systematic review. J Rheumatol Suppl 2011; 87: 317.
  • 35
    Ostergaard M, Poggenborg RP. Magnetic resonance imaging in psoriatic arthritis: update on current status and future perspectives: a report from the GRAPPA 2010 annual meeting. J Rheumatol 2012; 39: 40812.
  • 36
    Ostergaard M, Peterfy C, Conaghan P, McQueen F, Bird P, Ejbjerg B, et al. OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies: core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system. J Rheumatol 2003; 30: 13856.
  • 37
    Suter LG, Fraenkel L, Braithwaite RS. Role of magnetic resonance imaging in the diagnosis and prognosis of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2011; 63: 67588.
  • 38
    Suter LG, Fraenkel L, Braithwaite RS. Cost-effectiveness of adding magnetic resonance imaging to rheumatoid arthritis management. Arch Intern Med 2011; 171: 65767.
  • 39
    Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 96475.
  • 40
    Haraoui B, Pope J. Treatment of early rheumatoid arthritis: concepts in management. Semin Arthritis Rheum 2011; 40: 37188.
  • 41
    Van der Velde G, Pham B, Machado M, Ieraci L, Witteman W, Bombardier C, et al. Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review [review]. Arthritis Care Res (Hoboken) 2011; 63: 6578.
  • 42
    Finckh A, Bansback N, Liang MH. Cost-effectiveness of biologics in early rheumatoid arthritis [letter]. Ann Intern Med 2010; 152: 3334.
  • 43
    Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 2010; 62: 151526.
  • 44
    National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation; 2010. p. 136.
  • 45
    US Preventive Services Task Force. Screening for osteoporosis: US Preventive Services Task Force recommendation statement. Ann Intern Med 2011; 154: 35664.
  • 46
    Curtis JR, Carbone L, Cheng H, Hayes B, Laster A, Matthews R, et al. Longitudinal trends in use of bone mass measurement among older Americans, 1999-2005. J Bone Miner Res 2008; 23: 10617.
  • 47
    King AB, Fiorentino DM. Medicare payment cuts for osteoporosis testing reduced use despite tests' benefit in reducing fractures. Health Aff (Millwood) 2011; 30: 236270.
  • 48
    Schmajuk G, Yelin E, Chakravarty E, Nelson LM, Panopolis P, Yazdany J. Osteoporosis screening, prevention, and treatment in systemic lupus erythematosus: application of the systemic lupus erythematosus quality indicators. Arthritis Care Res (Hoboken) 2010; 62: 9931001.
  • 49
    Kanis JA, Johnell O, Oden A, Jonsson B, De Laet C, Dawson A. Prediction of fracture from low bone mineral density measurements overestimates risk. Bone 2000; 26: 38791.
  • 50
    Hillier TA, Stone KL, Bauer DC, Rizzo JH, Pedula KL, Cauley JA, et al. Evaluating the value of repeat bone mineral density measurement and prediction of fractures in older women: the study of osteoporotic fractures. Arch Intern Med 2007; 167: 15560.
  • 51
    Zhang J, Delzell E, Zhao H, Laster AJ, Saag KG, Kilgore ML, et al. Central DXA utilization shifts from office-based to hospital-based settings among Medicare beneficiaries in the wake of reimbursement changes. J Bone Miner Res 2012; 27: 85864.
  • 52
    Gourlay ML, Fine JP, Preisser JS, May RC, Li C, Lui LY, et al. Bone-density testing interval and transition to osteoporosis in older women. N Engl J Med 2012; 366: 22533.
  • 53
    Watts NB, Geusens P, Barton IP, Felsenberg D. Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD. J Bone Miner Res 2005; 20: 2097104.
  • 54
    Nelson HD, Helfand M, Woolf SH, Allan JD. Screening for postmenopausal osteoporosis: a review of the evidence for the US Preventive Services Task Force. Ann Intern Med 2002; 137: 52941.
  • 55
    Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 2002; 17: 110.
  • 56
    Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, et al. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 2004; 19: 12508.
  • 57
    Bates DW, Black DM, Cummings SR. Clinical use of bone densitometry: clinical applications. JAMA 2002; 288: 1898900.